ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
YONKERS, New York, April 03, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage…
Month: April 2023
BioCorRx Provides Business Update for 2022
Revenue Increases 343% for 2022 Due to Increased Number of Patients Treated at Licensed Clinics…
BioCorRx Provides Business Update for 2022
Revenue Increases 343% for 2022 Due to Increased Number of Patients Treated at Licensed Clinics…
Vaccinex Announces Private Placement with Commitments of $5.0 Million
ROCHESTER, N.Y., April 03, 2023 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the…
Vaccinex Announces Private Placement with Commitments of $5.0 Million
ROCHESTER, N.Y., April 03, 2023 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the…
Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
Carlsbad, CA, April 03, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing…
Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
Carlsbad, CA, April 03, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing…
A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases
HCW Biologics Published a Pivotal Scientific Paper in Aging Cell Subcutaneous Administration of HCW9218 Systemically…
A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases
HCW Biologics Published a Pivotal Scientific Paper in Aging Cell Subcutaneous Administration of HCW9218 Systemically…
PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023
PDS Biotech prepares to advance PDS0101 into a Phase 3 registrational clinical trial – VERSATILE-003…
PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023
PDS Biotech prepares to advance PDS0101 into a Phase 3 registrational clinical trial – VERSATILE-003…
NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V….
NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V….
Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in the Nordic Countries
Horus to increase ILUVIEN commercial presence with Nordic Retinal Specialists ATLANTA, April 03, 2023 (GLOBE…
Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in the Nordic Countries
Horus to increase ILUVIEN commercial presence with Nordic Retinal Specialists ATLANTA, April 03, 2023 (GLOBE…
Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting
NEW YORK and LONDON, April 03, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting
NEW YORK and LONDON, April 03, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors
Nes-Ziona, Israel, April 03, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex”), a…
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors
Nes-Ziona, Israel, April 03, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex”), a…
ORYZON Announces Positive Results from Planned Interim Analysis of PORTICO, a Phase 2b Adaptive Trial in Borderline Personality Disorder
Based on interim efficacy and safety data, Independent Data Monitoring Committee recommends continuation of the…